MAP2K7 and cancer: This pathway is also known as Ras-Raf-MEK-ERK pathway8, which is aberrantly activated in more than 30% of human cancers such as hepatocarcinoma (HCC), prostate carcinoma, non-small cell lung cancer (NSCLC), leukemia and melanoma.9